Table 4 HIV- and obstetric-related parameters, stratified according to antiretroviral third agent class

HIV RNA half-life decay, days

2.6 (1.6–11.5)

2.3 (1.4–5.3)

1.8 (1.1–6.0)

2.6 (1.8–10.3)

χ²(3) = 30.92, p < 0.001

PI vs NNRTI, p = 0.03

PI vs INSTI, p < 0.001

PI vs ABC/3TC/AZT, p = 0.87

NNRTI vs INSTI, p < 0.001

NNRTI vs ABC/3TC/AZT, p = 0.32

INSTI vs ABC/3TC/AZT, p = 0.03

Baseline pVL, log₁₀ copies/mL

4.2 (2.5–5.8)

4.3 (2.8–5.4)

5.0 (4.0–5.8)

3.8 (2.9–4.5)

χ²(3) = 28.14, p < 0.001

PI vs NNRTI, p = 0.13

PI vs INSTI, p < 0.001

PI vs ABC/3TC/AZT, p = 0.04

NNRTI vs INSTI, p = 0.18

NNRTI vs ABC/3TC/AZT, p = 0.03

INSTI vs ABC/3TC/AZT, p < 0.001

Baseline CD4⁺ T-cell count, cells/µL

359 (63–1136)

207 (30–848)

215 (10–700)

574 (290–1008)

χ²(3) = 31.20, p < 0.001

PI vs NNRTI, p < 0.001

PI vs INSTI, p = 0.28

PI vs ABC/3TC/AZT, p = 0.03

NNRTI vs INSTI, p = 0.56

NNRTI vs ABC/3TC/AZT, p < 0.001

INSTI vs ABC/3TC/AZT, p = 0.06

Gestational age when cART was started, weeks

21.2 (5.7–39.6)

18.9 (4.9–34.0)

17.6 (8.1–34.4)

21.9 (10.9–24.0)

χ²(3) = 3.67, p = 0.299

pVL 14 days after cART was initiated, log₁₀ HIV RNA copies/mL

2.5 (1.5–4.1)

2.5 (1.8–3.6)

2.4 (1.5–4.3)

1.9 (1.7–2.9)

χ²(3) = 6.94, p = 0.074

Time taken to reach pVL < 50 copies/mL, days^a

51.5 (7–174)

51.5 (21–188)

27.5 (6–121)

32.5 (21–63)

χ²(3) = 12.99, p = 0.005

PI vs NNRTI, p = 0.63

PI vs INSTI, p = 0.09

PI vs ABC/3TC/AZT, p = 0.07

NNRTI vs INSTI, p = 0.05

NNRTI vs ABC/3TC/AZT, p = 0.35

INSTI vs ABC/3TC/AZT, p = 0.45

Women with pVL < 50 copies/mL at 36 weeks’ gestation

95 (72.0)

21 (65.6)

13 (76.5)

11 (100)

p = 0.13

Women with pVL < 50 copies/mL at delivery

113 (85.6)

24 (75.0)

16 (94.1)

11 (100)

p = 0.17

Values are median (range) or total (%)